Finance Watch: Q1 Biopharma Venture Capital Dips From All-Time High, But Numbers Still Impress

Private Company Edition: Biotech companies raised $3.9bn, down from $4.6bn in the first quarter of 2019 – a record-breaking year in the US – but dollars per deal stayed above $20m for a second year. Also, Fusion has April's second $100m-plus VC financing with a $105m Series B.

Finance Watch

The amount of venture capital raised in the US by biopharmaceutical companies fell 15.2% to $3.9bn in the first quarter of 2019, but it still was an impressive quarter, ranking as the second-largest first quarter ever for the industry with an average deal size that remained above $20m for the second year in a row.

The first quarter of this year had a lot to live up to after 136 biopharma firms raised $4.6bn in the first three months of 2018. (Also see "Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year" - Scrip, 15 April, 2018

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business